To validate additional top-ranked candidate genes, six ICB therapy-related cohorts were collected (Additional file 1: Table S12), totaling 399 samples treated with CTLA-4 or PD1/PD-L1 inhibitors in skin cutaneous melanoma (SKCM), clear cell renal cell carcinoma (ccRCC), and non-small cell lung carcinoma (NSCLC) [62–67]. The gene discussed is CTLA4; the disease is clear cell renal carcinoma.